| CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究 |
| |
| 引用本文： | 王莹莹,程光华,濮之晨,葛俊亮,谢彦,陈晓磊. CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究[J]. 金属学报, 2015, 20(5): 552-556 |
| |
| 作者姓名： | 王莹莹 程光华 濮之晨 葛俊亮 谢彦 陈晓磊 |
| |
| 作者单位： | 1.皖南医学院弋矶山医院核医学科, ;2.皖南医学院弋矶山医院临床药学部, 芜湖 241000,安徽 |
| |
| 摘 要： | 目的: 研究CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬(tamoxifen, TAM)治疗乳腺癌患者生存率的相关性研究。方法: 选择2009至2004年本院甲乳外科和肿瘤内科收治的171名术后服用TAM治疗的雌激素阳性乳腺癌患者,调查TAM使用情况和生存状态等相关资料;收集相关的石蜡组织切片用于DNA提取;用PCR技术检测CYP2D6*10和CYP2C19*2基因型多态性;查明CYP2D6*10和CYP2C19*2基因型多态性与患者生存率的相关性。结果: 本次研究中,CYP2D6Wt/Wt、CYP2D6Wt/*10和CYP2D6*10/*10基因型的总生存率(overall survival,OS)类似,差异无统计学意义(P>0.05)。CYP2C19*2/*2基因型的5年OS明显优于CYP2C19 Wt/Wt,差异具有统计学意义(P<0.05);CYP2C19*2/*2基因型的10年OS明显优于CYP2C19 Wt/Wt和CYP2C19 Wt/*2,差异具有统计学意义(P<0.05);但是CYP2C19Wt/Wt与CYP2C19 Wt/*2的5、10年OS差异无统计学意义(P>0.05)。结论: 研究结果显示,CYP2D6*10基因型多态性与服用TAM治疗乳腺癌患者的生存率之间不存在相关性;CYP2C19*2基因型多态性与接受TAM治疗乳腺癌患者的生存率之间存在相关性,CYP2C19*2/*2接受TAM治疗乳腺癌患者的生存率最高,CYP2C19 Wt/*2生存率较高,CYP2C19 Wt/Wt较低。
|
| 关 键 词： | CYP2D6*10 CYP2C19*2 乳腺癌 他莫昔芬 |
| 收稿时间： | 2014-03-25 |
| 修稿时间： | 2014-10-10 |
Association between CYP2D6*10/CYP2C19*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment |
| |
| WANG Ying-ying,CHENG Guang-hua,PU Zhi-chen,GE Jun-liang,XIE Yan,CHEN Xiao-lei. Association between CYP2D6*10/CYP2C19*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment[J]. Acta Metallurgica Sinica, 2015, 20(5): 552-556 |
| |
| Authors: | WANG Ying-ying CHENG Guang-hua PU Zhi-chen GE Jun-liang XIE Yan CHEN Xiao-lei |
| |
| Affiliation: | 1. Department of Nuclear Medicine, Yijishan Hospital, Wannan Medical College, ;2. Department of Clinical Medicine, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China |
| |
| Abstract: | AIM: To observe the association between CYP2D6*10 and CYP2C19*2 genotype polymorphism and survival of breast cancer patient receiving tamoxifen (TAM) treatment.METHODS: 171 cases of breast cancer patient receiving TAM treatment were selected from breast surgery and medical oncology since 2004-2009. The service condition of TAM treatment and the survival state were examined, the paraffin section of patients were collected and used in DNA extract, the CYP2D6*10 and CYP2C19*2 genotype polymorphism were detected by PCR, and the association between CYP2D6*10 and CYP2C19*2 genotype polymorphism and survival of breast cancer patient receiving TAM treatment were ascertained.RESULTS: Overall survival (OS) of CYP2D6Wt/Wt, CYP2D6Wt/*10 and CYP2D6*10/*10 were very similar (P>0.05). 5 years-OS of CYP2C19*2/*2 were significantly higher than that of CYP2C19 Wt/Wt group, and the difference was statistically significant (P<0.05); 10 years-OS of CYP2C19*2/*2 were significantly higher than that of CYP2C19 Wt/Wt or CYP2C19 Wt/*2,and the difference was statistically significant (P<0.05); 5 or 10 years-OS of CYP2C19 Wt/Wt was similar to that of CYP2C19 Wt/*2 (P>0.05).CONCLUSION: The CYP2D6*10 genotype polymorphisms isn't associated with survival of breast cancer patient receiving TAM treatment. The CYP2C19*2 genotype polymorphism is associated with survival of breast cancer patient receiving TAM treatment. The survival rate of breast cancer patient with CYP2C19*2/*2 receiving TAM treatment is the highest, that of CYP2C19 Wt/*2 is medium, and that of CYP2C19 Wt/Wt is lower. |
| |
| Keywords: | CYP2D6*10 CYP2C19*2 breast cancer tamoxifen |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
